Rudolf Tauber
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rudolf Tauber has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
F. H. Perschel
Charité – Universitätsmedizin Berlin Campus Virchow-Klinikum
88 shared publications- Jens Dernedde
Institut für Laboratoriumsmedizin, klinische Chemie und Pathobiochemie, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
3 shared publications - Véronique Blanchard
Institute of Diagnostic Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany
3 shared publications - Burak Boyraz
Institut für Laboratoriumsmedizin, Klinische Chemie und Pathobiochemie, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Augustenburger Platz 1, 13353 Berlin, Germany
2 shared publications A. F. H. Pfeiffer
1 shared publicationAlfred Mokomba
Department of Obstetrics and Gynecology, Kenyatta National Hospital, Ngong Road, P.O. Box 20723, Nairobi 00202, Kenya
1 shared publication
Latest Publications
- Open Access
- 10 December 2025
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 25 (1) , 99-108
High-Mannose N -Glycans To Monitor Early Response to Chemotherapy in African Epithelial Ovarian Cancer Patients─A Pilot Study
Epithelial ovarian cancer (EOC) remains the most lethal form of cancer despite improvements in surgical techniques and therapeutic interventions over recent decades. The high mortality rate is largely associated with a lack of sensitive and specific early diagnostic biomarkers to allow timely intervention. Hence, the identification and validation of novel noninvasive biomarkers for primary diagnosis and for disease monitoring is of high importance. Malignant transformations of N-glycosylation have been reported across various cancer types including EOC, but little is known about the N-glycome of African populations. In this work, we investigated aberrant N-glycosylation for the first time in an African EOC cohort comprising primary patients and those undergoing chemotherapy. In this pilot study, the N-glycome of African EOC and controls was comparable to those previously found in European cohorts. Of importance, high-mannose N-glycans increased with response to treatment in early chemotherapy cycles, and complex-type sialylated fucosylated N-glycans decreased, especially in the late chemotherapy cycles. Interestingly, the glycan-based index that we previously developed to detect primary EOC was more sensitive and specific than the routine diagnostic biomarker to identify primary EOC and to monitor chemoresponse in the early phase of the treatment.
- 10 December 2025
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 25 (1) , 99-108
Open AccessHigh-Mannose N -Glycans To Monitor Early Response to Chemotherapy in African Epithelial Ovarian Cancer Patients─A Pilot Study
Epithelial ovarian cancer (EOC) remains the most lethal form of cancer despite improvements in surgical techniques and therapeutic interventions over recent decades. The high mortality rate is largely associated with a lack of sensitive and specific early diagnostic biomarkers to allow timely intervention. Hence, the identification and validation of novel noninvasive biomarkers for primary diagnosis and for disease monitoring is of high importance. Malignant transformations of N-glycosylation have been reported across various cancer types including EOC, but little is known about the N-glycome of African populations. In this work, we investigated aberrant N-glycosylation for the first time in an African EOC cohort comprising primary patients and those undergoing chemotherapy. In this pilot study, the N-glycome of African EOC and controls was comparable to those previously found in European cohorts. Of importance, high-mannose N-glycans increased with response to treatment in early chemotherapy cycles, and complex-type sialylated fucosylated N-glycans decreased, especially in the late chemotherapy cycles. Interestingly, the glycan-based index that we previously developed to detect primary EOC was more sensitive and specific than the routine diagnostic biomarker to identify primary EOC and to monitor chemoresponse in the early phase of the treatment.
- 30 May 2025
- Published by Springer Nature
- p. 243-293
Glycosylation in Cancer
Structural alterations of the glycan chains attached to glycoproteins and glycolipids are present in all types of malignomas investigated to date, including adenocarcinomas, sarcomas and haematological malignancies. They occur in humans as well as in animals including experimental models of malignancy, regardless of the type, cause, or stage of the tumour. The biochemical and genomic characterization of the enzymatic machineries involved in glycan biosynthesis in cancer cells shows that tumour-associated glycosylation changes are a critical part of tumour initiation and progression. Experimental studies and epidemiological findings give clear evidence that tumour-associated glycans bear functional significance in the invasive and metastatic growth of malignancies, for immunological tumour defence and, hence, influence the clinical outcome and the prognosis of cancer patients. Tumour-associated glycan changes are, moreover, targets for new pharmacological and immunological therapy methods and serve as important clinical biomarkers for diagnosis, particularly for monitoring disease progression and therapeutic efficacy. This chapter provides an overview of the major types of changes of glycosylation, genetic and biochemical mechanisms contributing to cancer-associated glycosylation, functional consequences for tumour growth and the clinical significance in cancer diagnosis, monitoring and treatment.
- 30 May 2025
- Published by Springer Nature
- p. 243-293
Glycosylation in Cancer
Structural alterations of the glycan chains attached to glycoproteins and glycolipids are present in all types of malignomas investigated to date, including adenocarcinomas, sarcomas and haematological malignancies. They occur in humans as well as in animals including experimental models of malignancy, regardless of the type, cause, or stage of the tumour. The biochemical and genomic characterization of the enzymatic machineries involved in glycan biosynthesis in cancer cells shows that tumour-associated glycosylation changes are a critical part of tumour initiation and progression. Experimental studies and epidemiological findings give clear evidence that tumour-associated glycans bear functional significance in the invasive and metastatic growth of malignancies, for immunological tumour defence and, hence, influence the clinical outcome and the prognosis of cancer patients. Tumour-associated glycan changes are, moreover, targets for new pharmacological and immunological therapy methods and serve as important clinical biomarkers for diagnosis, particularly for monitoring disease progression and therapeutic efficacy. This chapter provides an overview of the major types of changes of glycosylation, genetic and biochemical mechanisms contributing to cancer-associated glycosylation, functional consequences for tumour growth and the clinical significance in cancer diagnosis, monitoring and treatment.
- Open Access
- 25 January 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (2) , 178
Identification of an Immunoglobulin Paratope Binding to Keratan Sulfate and Expression of a Single-Chain Derivative for Imaging
Keratan sulfate (KS) is a negatively charged carbohydrate linked to proteins. Several KS-bearing structural glycosaminoglycans participate to maintain the homeostasis of a functional extracellular matrix. Dysfunction of its biochemical composition and structure might therefore lead to pathological situations. For this reason, imaging of KS in tissues is an important diagnostic tool. Here, we describe the identification of the KS paratope derived from the ancestral anti-KS IgG mAb MZ15, as well as the engineering, functional recombinant expression in E. coli, and purification of an anti-KS single-chain variable fragment (ScFv). The ScFv enabled in vitro imaging of KS in cryosections of rat cornea by immunofluorescence microscopy comparable to the ancestral IgG MZ15.
- 25 January 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (2) , 178
Open AccessIdentification of an Immunoglobulin Paratope Binding to Keratan Sulfate and Expression of a Single-Chain Derivative for Imaging
Keratan sulfate (KS) is a negatively charged carbohydrate linked to proteins. Several KS-bearing structural glycosaminoglycans participate to maintain the homeostasis of a functional extracellular matrix. Dysfunction of its biochemical composition and structure might therefore lead to pathological situations. For this reason, imaging of KS in tissues is an important diagnostic tool. Here, we describe the identification of the KS paratope derived from the ancestral anti-KS IgG mAb MZ15, as well as the engineering, functional recombinant expression in E. coli, and purification of an anti-KS single-chain variable fragment (ScFv). The ScFv enabled in vitro imaging of KS in cryosections of rat cornea by immunofluorescence microscopy comparable to the ancestral IgG MZ15.
- Open Access
- 30 July 2022
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-11
HE4 as a serum biomarker for the diagnosis of pelvic masses: a prospective, multicenter study in 965 patients
Background: To evaluate the diagnostic value of adding human epididymis protein 4 (HE4), cancer antigen 125 (CA125) and risk of malignancy algorithm (ROMA) to ultrasound for detecting ovarian cancer in patients with a pelvic mass. Methods: This was a prospective, observational, multicenter study. Patients aged > 18 years who were scheduled to undergo surgery for a suspicious pelvic mass had CA125 and HE4 levels measured prior to surgery, in addition to a routine transvaginal ultrasound scan. The diagnostic performance of CA125, HE4 and ROMA for distinguishing between benign and malignant adnexal masses was assessed using receiver operating characteristic (ROC) analysis and the corresponding area under the curve (AUC). Results: Of 965 evaluable patients, 804 were diagnosed with benign tumors and 161 were diagnosed with ovarian cancer. In late-stage ovarian cancer, CA125, HE4 and ROMA all had an excellent diagnostic performance (AUC > 0.92), whereas in stage I and II, diagnostic performance of all three biomarkers was less adequate (AUC < 0.77). In the differential diagnosis of ovarian cancer and endometriosis, ROMA and HE4 performed better than CA125 with 99 and 98.1% versus 75.0% sensitivity, respectively, at 75.4% specificity. Conclusions: ROMA and HE4 could be valuable biomarkers to help with the diagnosis of ovarian cancer in premenopausal patients in order to differentiate from endometriosis, whereas CA125 may be more adequate for postmenopausal patients.
- 30 July 2022
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-11
Open AccessHE4 as a serum biomarker for the diagnosis of pelvic masses: a prospective, multicenter study in 965 patients
Background: To evaluate the diagnostic value of adding human epididymis protein 4 (HE4), cancer antigen 125 (CA125) and risk of malignancy algorithm (ROMA) to ultrasound for detecting ovarian cancer in patients with a pelvic mass. Methods: This was a prospective, observational, multicenter study. Patients aged > 18 years who were scheduled to undergo surgery for a suspicious pelvic mass had CA125 and HE4 levels measured prior to surgery, in addition to a routine transvaginal ultrasound scan. The diagnostic performance of CA125, HE4 and ROMA for distinguishing between benign and malignant adnexal masses was assessed using receiver operating characteristic (ROC) analysis and the corresponding area under the curve (AUC). Results: Of 965 evaluable patients, 804 were diagnosed with benign tumors and 161 were diagnosed with ovarian cancer. In late-stage ovarian cancer, CA125, HE4 and ROMA all had an excellent diagnostic performance (AUC > 0.92), whereas in stage I and II, diagnostic performance of all three biomarkers was less adequate (AUC < 0.77). In the differential diagnosis of ovarian cancer and endometriosis, ROMA and HE4 performed better than CA125 with 99 and 98.1% versus 75.0% sensitivity, respectively, at 75.4% specificity. Conclusions: ROMA and HE4 could be valuable biomarkers to help with the diagnosis of ovarian cancer in premenopausal patients in order to differentiate from endometriosis, whereas CA125 may be more adequate for postmenopausal patients.
- Open Access
- 7 June 2022
- Published by MDPI AG in Infectious Disease Reports
- Vol. 14 (3) , 433-445
The Burden of Hepatitis B, Hepatitis C, and Human Immunodeficiency Viruses in Ovarian Cancer Patients in Nairobi, Kenya
Ovarian cancer (OC) is a gynecological malignancy characterized by high morbidity and mortalities due to late-stage diagnosis because accurate early diagnostic biomarkers are lacking. Testing of Hepatitis B virus (HBV), Hepatitis C virus (HCV), and Human immunodeficiency virus (HIV) infections in OC patients is pertinent in light of the emerging evidence of their contribution to poor prognosis. We, for the first time, investigated the prevalence of HBV, HCV, and HIV infections in a Kenyan cohort of OC to inform optimal management. We recruited a cohort of women above 18 years of age, comprising 86 OC patients and 50 healthy controls. Participants’ blood samples were serologically screened for HBV, HCV, and HIV. We found seroprevalence rates of 29.1%, 26.7%, and 1.2% for HBV, HIV, and HCV, respectively, in OC patients. The healthy control group had HBV and HIV seroprevalence rates of 3.9% for each with no positive HCV case. HBV/HIV coinfection was noted only in the OC group with a positivity rate of 17.4%. In summary, we found higher HBV and HIV seroprevalence in Kenyan OC patients compared to the healthy control group, whereas HCV prevalence was reflective of the general population. Hence, we recommend screening for HBV and HIV among OC patients destined for anticancer treatment.
- 7 June 2022
- Published by MDPI AG in Infectious Disease Reports
- Vol. 14 (3) , 433-445
Open AccessThe Burden of Hepatitis B, Hepatitis C, and Human Immunodeficiency Viruses in Ovarian Cancer Patients in Nairobi, Kenya
Ovarian cancer (OC) is a gynecological malignancy characterized by high morbidity and mortalities due to late-stage diagnosis because accurate early diagnostic biomarkers are lacking. Testing of Hepatitis B virus (HBV), Hepatitis C virus (HCV), and Human immunodeficiency virus (HIV) infections in OC patients is pertinent in light of the emerging evidence of their contribution to poor prognosis. We, for the first time, investigated the prevalence of HBV, HCV, and HIV infections in a Kenyan cohort of OC to inform optimal management. We recruited a cohort of women above 18 years of age, comprising 86 OC patients and 50 healthy controls. Participants’ blood samples were serologically screened for HBV, HCV, and HIV. We found seroprevalence rates of 29.1%, 26.7%, and 1.2% for HBV, HIV, and HCV, respectively, in OC patients. The healthy control group had HBV and HIV seroprevalence rates of 3.9% for each with no positive HCV case. HBV/HIV coinfection was noted only in the OC group with a positivity rate of 17.4%. In summary, we found higher HBV and HIV seroprevalence in Kenyan OC patients compared to the healthy control group, whereas HCV prevalence was reflective of the general population. Hence, we recommend screening for HBV and HIV among OC patients destined for anticancer treatment.
- 25 January 2022
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 5 (2) , 853-861
Imaging Keratan Sulfate in Ocular Tissue Sections by Immunofluorescence Microscopy and LA-ICP-MS
Carbohydrate-specific antibodies can serve as valuable tools to monitor alterations in the extracellular matrix resulting from pathologies. Here, the keratan sulfate-specific monoclonal antibody MZ15 was characterized in more detail by immunofluorescence microscopy as well as laser ablation ICP-MS using tissue cryosections and paraffin-embedded samples. Pretreatment with keratanase II prevented staining of samples and therefore demonstrated efficient enzymatic keratan sulfate degradation. Random fluorescent labeling and site-directed introduction of a metal cage into MZ15 were successful and allowed for a highly sensitive detection of the keratan sulfate landscape in the corneal stroma from rats and human tissue.
- 25 January 2022
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 5 (2) , 853-861
Imaging Keratan Sulfate in Ocular Tissue Sections by Immunofluorescence Microscopy and LA-ICP-MS
Carbohydrate-specific antibodies can serve as valuable tools to monitor alterations in the extracellular matrix resulting from pathologies. Here, the keratan sulfate-specific monoclonal antibody MZ15 was characterized in more detail by immunofluorescence microscopy as well as laser ablation ICP-MS using tissue cryosections and paraffin-embedded samples. Pretreatment with keratanase II prevented staining of samples and therefore demonstrated efficient enzymatic keratan sulfate degradation. Random fluorescent labeling and site-directed introduction of a metal cage into MZ15 were successful and allowed for a highly sensitive detection of the keratan sulfate landscape in the corneal stroma from rats and human tissue.
- Open Access
Plasma Proteome Fingerprints Reveal Distinctiveness and Clinical Outcome of SARS-CoV-2 Infection
Background: We evaluated how plasma proteomic signatures in patients with suspected COVID-19 can unravel the pathophysiology, and determine kinetics and clinical outcome of the infection. Methods: Plasma samples from patients presenting to the emergency department (ED) with symptoms of COVID-19 were stratified into: (1) patients with suspected COVID-19 that was not confirmed (n = 44); (2) non-hospitalized patients with confirmed COVID-19 (n = 44); (3) hospitalized patients with confirmed COVID-19 (n = 53) with variable outcome; and (4) patients presenting to the ED with minor diseases unrelated to SARS-CoV-2 infection (n = 20). Besides standard of care diagnostics, 177 circulating proteins related to inflammation and cardiovascular disease were analyzed using proximity extension assay (PEA, Olink) technology. Results: Comparative proteome analysis revealed 14 distinct proteins as highly associated with SARS-CoV-2 infection and 12 proteins with subsequent hospitalization (p < 0.001). ADM, IL-6, MCP-3, TRAIL-R2, and PD-L1 were each predictive for death (AUROC curve 0.80–0.87). The consistent increase of these markers, from hospital admission to intensive care and fatality, supported the concept that these proteins are of major clinical relevance. Conclusions: We identified distinct plasma proteins linked to the presence and course of COVID-19. These plasma proteomic findings may translate to a protein fingerprint, helping to assist clinical management decisions.
Open AccessPlasma Proteome Fingerprints Reveal Distinctiveness and Clinical Outcome of SARS-CoV-2 Infection
Background: We evaluated how plasma proteomic signatures in patients with suspected COVID-19 can unravel the pathophysiology, and determine kinetics and clinical outcome of the infection. Methods: Plasma samples from patients presenting to the emergency department (ED) with symptoms of COVID-19 were stratified into: (1) patients with suspected COVID-19 that was not confirmed (n = 44); (2) non-hospitalized patients with confirmed COVID-19 (n = 44); (3) hospitalized patients with confirmed COVID-19 (n = 53) with variable outcome; and (4) patients presenting to the ED with minor diseases unrelated to SARS-CoV-2 infection (n = 20). Besides standard of care diagnostics, 177 circulating proteins related to inflammation and cardiovascular disease were analyzed using proximity extension assay (PEA, Olink) technology. Results: Comparative proteome analysis revealed 14 distinct proteins as highly associated with SARS-CoV-2 infection and 12 proteins with subsequent hospitalization (p < 0.001). ADM, IL-6, MCP-3, TRAIL-R2, and PD-L1 were each predictive for death (AUROC curve 0.80–0.87). The consistent increase of these markers, from hospital admission to intensive care and fatality, supported the concept that these proteins are of major clinical relevance. Conclusions: We identified distinct plasma proteins linked to the presence and course of COVID-19. These plasma proteomic findings may translate to a protein fingerprint, helping to assist clinical management decisions.
- 16 November 2020
- Published by Taylor & Francis in Biomarkers
- Vol. 25 (8) , 616-625
Assessment of serum ferritin as a biomarker in COVID-19: bystander or participant? Insights by comparison with other infectious and non-infectious diseases
BACKGROUND: The 2019 coronavirus disease (COVID-19) caused by the SARS-CoV-2 virus has an impact on all aspects of patient care. Serum ferritin generally represents a biomarker of choice when iron deficiency is suspected. However, ferritin is also an acute-phase-protein exhibiting elevated serum concentrations in various inflammatory diseases. Here we focus on the role of serum ferritin for diagnostic and clinical management of patients with COVID-19 in comparison with other infectious and non-infectious diseases. METHODS: We examined scientific articles listed in PubMed reporting on ferritin in various infectious and non-infectious diseases. We then compared these results with nine current COVID-19 ferritin reports published in 2020. RESULTS: Several non-infectious as well as non-COVID-19 infectious diseases are characterized by a partly dramatic elevation of serum ferritin levels. All COVID-19 studies published between February and May 2020, which documented laboratory serum ferritin, indicate ferritin as a diagnostic biomarker of COVID-19 severity in hospitalized patients. CONCLUSIONS: Serum ferritin may be considered both a prognostic and stratifying biomarker that can also contribute to therapeutic decision-making concerning patients with COVID-19. It should be emphasized, however, that most scientific reports refer to cohorts in the Asian region. Further validation in other cohorts is urgently required.
- 16 November 2020
- Published by Taylor & Francis in Biomarkers
- Vol. 25 (8) , 616-625
Assessment of serum ferritin as a biomarker in COVID-19: bystander or participant? Insights by comparison with other infectious and non-infectious diseases
BACKGROUND: The 2019 coronavirus disease (COVID-19) caused by the SARS-CoV-2 virus has an impact on all aspects of patient care. Serum ferritin generally represents a biomarker of choice when iron deficiency is suspected. However, ferritin is also an acute-phase-protein exhibiting elevated serum concentrations in various inflammatory diseases. Here we focus on the role of serum ferritin for diagnostic and clinical management of patients with COVID-19 in comparison with other infectious and non-infectious diseases. METHODS: We examined scientific articles listed in PubMed reporting on ferritin in various infectious and non-infectious diseases. We then compared these results with nine current COVID-19 ferritin reports published in 2020. RESULTS: Several non-infectious as well as non-COVID-19 infectious diseases are characterized by a partly dramatic elevation of serum ferritin levels. All COVID-19 studies published between February and May 2020, which documented laboratory serum ferritin, indicate ferritin as a diagnostic biomarker of COVID-19 severity in hospitalized patients. CONCLUSIONS: Serum ferritin may be considered both a prognostic and stratifying biomarker that can also contribute to therapeutic decision-making concerning patients with COVID-19. It should be emphasized, however, that most scientific reports refer to cohorts in the Asian region. Further validation in other cohorts is urgently required.
- Open Access
- 27 April 2020
- Published by Wiley in Transfusion
- Vol. 60 (8) , 1828-1836
Pooling, room temperature, and extended storage time increase the release of adult‐specific biologic response modifiers in platelet concentrates: a hidden transfusion risk for neonates?
BACKGROUND Adult donor platelets (PLTs) are frequently transfused to prevent or stop bleeding in neonates with thrombocytopenia. There is evidence for PLT transfusion–related morbidity and mortality, leading to the hypothesis on immunomodulatory effects of transfusing adult PLTs into neonates. Candidate factors are biologic response modifiers (BRMs) that are expressed at higher rates in adult than in neonatal PLTs. This study investigated whether storage conditions or preparation methods impact on the release of those differentially expressed BRMs. STUDY DESIGN AND METHODS Pooled PLT concentrates (PCs) and apheresis PCs (APCs) were stored under agitation for up to 7 days at room temperature (RT) or at 2 to 8°C. The BRMs CCL5/RANTES, TGFβ1, TSP1, and DKK1 were measured in PCsʼ supernatant, lysate, and corresponding plasma. PLT function was assessed by light transmission aggregometry. RESULTS Concerning the preparation method, higher concentrations of DKK1 were found in pooled PCs compared to APCs. In supernatants, the concentrations of CCL5, TGFβ1, TSP1, and DKK1 significantly increased, both over standard (≤4 days) and over extended storage times (7 days). Each of the four BRMs showed an up to twofold increase in concentration after storage at RT compared to cold storage (CS). There was no difference in the aggregation capacity. CONCLUSION This analysis shows that the release of adult‐specific BRMs during storage is lowest in short‐ and CS APCs. Our study points to strategies for reducing the exposure of sick neonates to BRMs that can be specifically associated to PLT transfusion–related morbidity.
- 27 April 2020
- Published by Wiley in Transfusion
- Vol. 60 (8) , 1828-1836
Open AccessPooling, room temperature, and extended storage time increase the release of adult‐specific biologic response modifiers in platelet concentrates: a hidden transfusion risk for neonates?
BACKGROUND Adult donor platelets (PLTs) are frequently transfused to prevent or stop bleeding in neonates with thrombocytopenia. There is evidence for PLT transfusion–related morbidity and mortality, leading to the hypothesis on immunomodulatory effects of transfusing adult PLTs into neonates. Candidate factors are biologic response modifiers (BRMs) that are expressed at higher rates in adult than in neonatal PLTs. This study investigated whether storage conditions or preparation methods impact on the release of those differentially expressed BRMs. STUDY DESIGN AND METHODS Pooled PLT concentrates (PCs) and apheresis PCs (APCs) were stored under agitation for up to 7 days at room temperature (RT) or at 2 to 8°C. The BRMs CCL5/RANTES, TGFβ1, TSP1, and DKK1 were measured in PCsʼ supernatant, lysate, and corresponding plasma. PLT function was assessed by light transmission aggregometry. RESULTS Concerning the preparation method, higher concentrations of DKK1 were found in pooled PCs compared to APCs. In supernatants, the concentrations of CCL5, TGFβ1, TSP1, and DKK1 significantly increased, both over standard (≤4 days) and over extended storage times (7 days). Each of the four BRMs showed an up to twofold increase in concentration after storage at RT compared to cold storage (CS). There was no difference in the aggregation capacity. CONCLUSION This analysis shows that the release of adult‐specific BRMs during storage is lowest in short‐ and CS APCs. Our study points to strategies for reducing the exposure of sick neonates to BRMs that can be specifically associated to PLT transfusion–related morbidity.
- 1 September 2019
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 292 (3) , 664-672
Kidney Injury after Intravenous versus Intra-arterial Contrast Agent in Patients Suspected of Having Coronary Artery Disease: A Randomized Trial
In patients suspected of having coronary artery disease, intravenous contrast agent administration for coronary CT angiography had a lower rate of acute kidney injury compared with intra-arterial c... Background In the absence of randomized studies, it has been controversial whether the likelihood of acute kidney injury (AKI) differs between intravenous and intra-arterial contrast agent administ...
- 1 September 2019
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 292 (3) , 664-672
Kidney Injury after Intravenous versus Intra-arterial Contrast Agent in Patients Suspected of Having Coronary Artery Disease: A Randomized Trial
In patients suspected of having coronary artery disease, intravenous contrast agent administration for coronary CT angiography had a lower rate of acute kidney injury compared with intra-arterial c... Background In the absence of randomized studies, it has been controversial whether the likelihood of acute kidney injury (AKI) differs between intravenous and intra-arterial contrast agent administ...